RATIONALE: β2-Agonists are the treatment of choice for exercise-induced bronchoconstriction (EIB) and act through specific receptors (ADRB2). Arg16Gly polymorphisms have been shown to affect responses to regular use of β2-agonists. OBJECTIVES: To evaluate the influence of the Arg16Gly receptor polymorphism on salmeterol bronchoprotection in EIB and assess predictors of bronchoprotection. METHODS: A prospective, genotype-blinded, randomized trial was performed in 26 subjects (12 Arg16Arg and 14 Gly16Gly) with EIB who were not on controller therapy. Subjects were administered salmeterol, 50 μg twice a day for 2 weeks, and underwent an exercise challenge 9 hours after the first and last drug dose. In addition to genotype, FEV1, response to salmeterol, degree of EIB, and exhaled nitric oxide (FE(NO)) at baseline were examined for their association with loss of bronchoprotection (LOB). MEASUREMENTS AND MAIN RESULTS: The maximum exercise-induced FEV1 fall was 27.9 ± 1.4% during the run-in period, 8.1 ± 1.2% (70.3 ± 4.1% bronchoprotection) after the first salmeterol dose, and 22.8 ± 3.2% (18.9 ± 11.5% bronchoprotection) after 2 weeks of salmeterol (P = 0.0001). The Arg16Gly polymorphisms were not associated with the LOB in response to salmeterol. FeNO values at baseline were significantly related to the LOB (r = 0.47; P = 0.01). Mean change was a 74 ± 13% LOB in subjects with FE(NO) levels greater than 50 ppb and a 7 ± 16% gain in bronchoprotection in those with FE(NO) levels less than 25 ppb (P = 0.01). CONCLUSIONS: The LOB that occurs with chronic long-acting β2-agonists use is not affected by ADRB2 Arg16Gly polymorphisms. High FE(NO) was associated with marked LOB. Use of long-acting β2-agonists before achieving a reduction in FeNO may need to be avoided. Clinical trial registered with www.clinicaltrials.gov (NCT 00595361).
RCT Entities:
RATIONALE: β2-Agonists are the treatment of choice for exercise-induced bronchoconstriction (EIB) and act through specific receptors (ADRB2). Arg16Gly polymorphisms have been shown to affect responses to regular use of β2-agonists. OBJECTIVES: To evaluate the influence of the Arg16Gly receptor polymorphism on salmeterol bronchoprotection in EIB and assess predictors of bronchoprotection. METHODS: A prospective, genotype-blinded, randomized trial was performed in 26 subjects (12 Arg16Arg and 14 Gly16Gly) with EIB who were not on controller therapy. Subjects were administered salmeterol, 50 μg twice a day for 2 weeks, and underwent an exercise challenge 9 hours after the first and last drug dose. In addition to genotype, FEV1, response to salmeterol, degree of EIB, and exhaled nitric oxide (FE(NO)) at baseline were examined for their association with loss of bronchoprotection (LOB). MEASUREMENTS AND MAIN RESULTS: The maximum exercise-induced FEV1 fall was 27.9 ± 1.4% during the run-in period, 8.1 ± 1.2% (70.3 ± 4.1% bronchoprotection) after the first salmeterol dose, and 22.8 ± 3.2% (18.9 ± 11.5% bronchoprotection) after 2 weeks of salmeterol (P = 0.0001). The Arg16Gly polymorphisms were not associated with the LOB in response to salmeterol. FeNO values at baseline were significantly related to the LOB (r = 0.47; P = 0.01). Mean change was a 74 ± 13% LOB in subjects with FE(NO) levels greater than 50 ppb and a 7 ± 16% gain in bronchoprotection in those with FE(NO) levels less than 25 ppb (P = 0.01). CONCLUSIONS: The LOB that occurs with chronic long-acting β2-agonists use is not affected by ADRB2 Arg16Gly polymorphisms. High FE(NO) was associated with marked LOB. Use of long-acting β2-agonists before achieving a reduction in FeNO may need to be avoided. Clinical trial registered with www.clinicaltrials.gov (NCT 00595361).
Authors: Elliot Israel; Vernon M Chinchilli; Jean G Ford; Homer A Boushey; Reuben Cherniack; Timothy J Craig; Aaron Deykin; Joanne K Fagan; John V Fahy; James Fish; Monica Kraft; Susan J Kunselman; Stephen C Lazarus; Robert F Lemanske; Stephen B Liggett; Richard J Martin; Nandita Mitra; Stephen P Peters; Eric Silverman; Christine A Sorkness; Stanley J Szefler; Michael E Wechsler; Scott T Weiss; Jeffrey M Drazen Journal: Lancet Date: 2004 Oct 23-29 Impact factor: 79.321
Authors: Giusy D Albano; Jinming Zhao; Emily B Etling; Seo Young Park; Haizhen Hu; John B Trudeau; Mirella Profita; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2015-03-24 Impact factor: 10.793
Authors: Juan Carlos Cardet; Xiaofeng Jiang; Quan Lu; Norma Gerard; Kristen McIntire; Homer A Boushey; Mario Castro; Vernon M Chinchilli; Christopher D Codispoti; Anne-Marie Dyer; Fernando Holguin; Monica Kraft; Stephen Lazarus; Robert F Lemanske; Njira Lugogo; Dave Mauger; Wendy C Moore; James Moy; Victor E Ortega; Stephen P Peters; Lewis J Smith; Julian Solway; Christine A Sorkness; Kaharu Sumino; Michael E Wechsler; Sally Wenzel; Elliot Israel Journal: J Allergy Clin Immunol Date: 2019-03-11 Impact factor: 10.793
Authors: Elliot Israel; Jessica Lasky-Su; Amy Markezich; Amy Damask; Stanley J Szefler; Brooke Schuemann; Barbara Klanderman; Jody Sylvia; Shamsah Kazani; Rongling Wu; Fernando Martinez; Homer A Boushey; Vernon M Chinchilli; Dave Mauger; Scott T Weiss; Kelan G Tantisira Journal: Am J Respir Crit Care Med Date: 2015-03-01 Impact factor: 30.528